Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...

The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...

Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...

Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following ...

The health care industry has invested heavily in point solutions ($100 billion). We have one tool for scheduling, another for ...

Carl Valenstein is a partner with Morgan Lewis and co-leads the firm’s Environmental, Social, and Governance (ESG) & Sustainability team. Shabeena Sharak, a summer associate with the firm, contributed ...

An oversubscribed $70 million Series B, co-led by Alpha Wave and YK Bioventures with Eli Lilly participation, funds clinical ...

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...

This June, ten of the life sciences industry’s most respected board members came to New York for Accenture’s second annual Life Sciences Board Forum for something this industr ...

Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...

Ultragenyx is reviewing program disposition and implementing significant expense reductions as brokerages cut price targets ...

GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type 2 diabetes. For many patients, the drugs remain a highly effective ...